Treatment of dyslipidemia
For inpatient diagnostics and treatment of foreign citizens you can contact us the following ways:
Tel: +375(33)350-98-44
Skype: cardio-minsk
E-mail: ovbd@cardio.by
From 25.01.2022 in RSPC "Cardiology" a new paid medical service has been introduced: the use of the original drug inclisiran registered on the territory of the Republic of Belarus on 10.08.2021 under the trade name "Sibrava" for treatment of patients with severe lipid metabolism disorders for the primary and secondary prevention of cardiovascular events.
Inclisiran is a new hypolipidemic drug, the first representative of a completely new class of drugs. It is a small interfering RNA (siRNA) that suppresses expression of the gene encoding PCSK9 with the so-called RNA interference mechanism. Inclisiran turns off or silences the PCSK9 gene, causing the liver to absorb more "bad" low-density cholesterol from the blood and break it down.
Inclisiran is prescribed in addition to a cholesterol-lowering diet and is used in the following combinations:
- Together with a statin (a cholesterol-lowering drug), sometimes in combination with another cholesterol-lowering drug (ezetimibe) if the maximum statin dose does not work well enough, or
- alone or together with other cholesterol-lowering drugs when statins don't work well or can't be used.
Inclisiran is available as a pre-filled syringe for subcutaneous injection containing 284 mg of Inclisiran in 1.5 ml of solution.
The recommended dose is 284 mg of inclisiran, which is administered as a single subcutaneous injection. After the first injection, the drug is administered again after 3 months and then every 6 months.
According to the 2019 European Society of Cardiology guidelines for the management of dyslipidemias inclisiran is effective for patients with dyslipidemia when target levels of low density lipoproteins are not achieved against the background of combined hypolipidemic therapy (statins + ezetimibe) in patients with cardiovascular diseases of atherosclerotic nature, familial hypercholesterolemia, or high cardiovascular risk (type 2 diabetes, 20% cardiovascular event risk within 10-year period, chronic kidney disease, etc. ), as well as in case of intolerance to statins.
In the ORION-9, -10, -11 group of clinical trials, inclisiran administration was found to reduce LDL-C levels by 50-58%, both in the short and long term. The safety profile of inclisiran is comparable to placebo, and there were no data on the occurrence of specific serious adverse events that occurred during treatment.
